Philip Leipprandt, DO
Gastroenterology · Pikeville, KYNPI 1528217890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 558 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by AbbVie at 28.8% of the total.
Across 558 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$768
- Daiichi Sankyo Inc.$413
- Merck$345
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$337
- plus $3K from 35 others
What the payments were for
- Consulting fees$861%
- Food & beverage$8,65797%
- Education$1832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 226 | $2,567 |
| Johnson & Johnson(2 entities) | 67 | $1,438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $768 |
| Daiichi Sankyo Inc. | 32 | $413 |
| Merck | 21 | $345 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $337 |
| Covidien LP | 8 | $310 |
| Intercept Pharmaceuticals, Inc. | 14 | $269 |
| Nestle Healthcare Nutrition Inc. | 14 | $248 |
| Regeneron Healthcare Solutions, Inc. | 13 | $246 |
| Boston Scientific | 10 | $200 |
| Lilly USA, LLC | 10 | $183 |
| Ardelyx, Inc. | 8 | $153 |
| Urogen Pharma, Inc. | 6 | $150 |
| Phathom Pharmaceuticals, Inc. | 9 | $139 |
| Gilead | 6 | $133 |
| Endo USA, Inc. | 6 | $128 |
| Madrigal Pharmaceuticals | 6 | $109 |
| Pfizer | 7 | $104 |
| Medtronic | 4 | $101 |
| Sanofi | 5 | $90 |
| Janssen Scientific Affairs, LLC | 1 | $90 |
| Evoke Pharma, Inc. | 1 | $68 |
| UCB, Inc. | 3 | $45 |
| Organogenesis Inc. | 2 | $30 |
| Leica Microsystems Inc. | 1 | $27 |
| Edwards Lifesciences | 1 | $23 |
| GSK | 1 | $21 |
| Baxter Healthcare | 1 | $18 |
| Calyxo, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $16 |
| Vertex | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| ERBE USA Inc | 1 | $15 |
| Solventum Corporation | 1 | $15 |
| Olympus America Inc. | 1 | $14 |
| Convatec Inc. | 1 | $13 |
| CSL Behring | 1 | $13 |
| Vivus LLC | 1 | $11 |
How this compares
$8,926 in reported general payments places this provider in the 75th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 71 | $224,765 |
| XifaxanRifaximin | 45 | $147,228 |
| ZenpepLipase/Protease/Amylase | 20 | $58,021 |
| LinzessLinaclotide | 73 | $41,032 |
| MovantikNaloxegol Oxalate | 42 | $16,631 |
| MotegrityPrucalopride Succinate | 16 | $9,603 |
| VoqueznaVonoprazan Fumarate | 12 | $7,585 |
| Scopolamine | 28 | $3,776 |
| Dexlansoprazole DrDexlansoprazole | 20 | $3,191 |
| Sucralfate | 14 | $1,347 |
| Pantoprazole Sodium | 151 | $1,244 |
| Budesonide DrBudesonide | 12 | $1,158 |
| Dicyclomine Hcl | 41 | $1,106 |
| Colesevelam Hcl | 15 | $1,041 |
| Famotidine | 56 | $738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,567 | $265,797144 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $337 | $147,22845 claims |
| Redhill Biopharma Inc.Movantik | $16 | $16,63142 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $768 | $9,60316 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $139 | $7,58512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Pikeville
- Gerald DrydenLouisville$2.1M
- Zahid SaeedCrestview Hills$442K
- Matthew CaveLouisville$340K
- Michael KreaseLouisville$322K
- Sunana SohiLouisville$220K
- Jeffrey TuvlinLouisville$202K
- Stephen McClaveLouisville$124K
- Uday ShankarHazard$64K
- Terrence BarrettLexington$57K
- Avinash AravantagiBowling Green$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.